ROR1 and B-cell chronic lymphocytic leukemia: However, Cirmtuzumab, a humanized high affinity anti-ROR1 monoclonal antibody directed toward the immunoglobulin-like domain of ROR1, has been safely administered to 12 patients with CLL with no significant toxicity reported (NCT02222688).39